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This report constitutes a prospectively planned meta-analysis combining two almost identical trials undertaken in Australasia and
Canada to study the effect of starting chemotherapy immediately in asymptomatic patients with metastatic colorectal cancer. Patients
(n¼168) were randomised to receive either immediate or delayed treatment (at onset of predefined symptoms). Australasian
patients received either weekly 5-fluorouracil and leucovorin (500 and 20mgm
 2, respectively) (n¼59) or the daily 5 Mayo Clinic
schedule (425 and 20mgm
 2, respectively) (n¼42). Canadian patients were treated with the Mayo schedule (n¼67). Otherwise,
the two studies were almost identical in design and each used the European Organisation for the Research and Treatment of Cancer
(EORTC) QLQ-C30 instrument for measuring quality of life (QoL). Treatment was continued until 6 months had elapsed or disease
progression occurred. Low accrual led to trial suspension before the predetermined sample size for either study was reached. Median
survival was not significantly better with immediate treatment (median 13.0 vs 11.0 months; hazard ratio, 1.15; 95% confidence
interval (CI) 0.79–1.72; P¼0.49). There was no statistically significant difference in progression-free survival (time from
randomisation until first evidence of progression after chemotherapy, 10.2 vs 10.8 months; hazard ratio, 1.08; 95% CI 0.71–1.64;
P¼0.73). There was no difference in overall QoL or its individual domains between the two treatment strategies at baseline or at any
subsequent time point. Early treatment of asymptomatic patients with metastatic colorectal cancer did not provide a survival benefit
or improved QoL compared to withholding treatment until symptoms occurred.
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Colorectal cancer (CRC) is the most common malignancy in
Western countries. Primary disease, detected early, is potentially
curable surgically. However, about 20% of patients have metastatic
disease at initial presentation, and about 50% of all stage A–C
disease ultimately recur despite surgery and adjuvant therapy.
Most of these patients have incurable metastases. Until recently,
the most active cytotoxic agent against metastatic CRC was 5-
fluorouracil (5FU) potentiated by leucovorin (LV, folinic acid)
(Rustum, 1989). A number of clinical trials and three meta-
analyses have shown improved response rates with 5FU–LV
compared with 5FU alone (Piedbois et al, 1992; Jonker et al, 2000;
Thirion et al, 2004). In addition, quality of life (QoL) can be
improved as a consequence of tumour response or stabilisation by
chemotherapy (Scheithauer et al, 1993; Glimelius et al, 1995). One
of these meta-analyses suggested a greater treatment effect on
survival advantage for poor performance status (Eastern Coopera-
tive Oncology Group (ECOG) 2þ) patients, with a treatment effect
on good performance status patients that was similar (Thirion
et al, 2004).
In asymptomatic patients, chemotherapy may be given im-
mediately on diagnosis of incurable metastatic disease or may be
withheld until symptoms develop. The appropriate timing of the
use of ‘expectant’ chemotherapy has been the subject of debate,
especially when the potential toxicity of treatment is taken into
account. The Nordic Gastrointestinal Tumor Adjuvant Therapy
Group (1992) addressed this issue in a randomised controlled trial
in 183 patients with advanced but asymptomatic CRC. The results
of this study suggested a survival benefit for patients receiving
early treatment with methotrexate and 5FU–LV (MFL), but there
were methodological issues: only 57% of patients randomised to
expectant treatment received chemotherapy; chemotherapy was not
standardised; outcomes were poorer than expected in the expectant
treatment group; and no formal QoL analyses were published.
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sIn a separate study from Finland, the response rate to an
epirubicin, methotrexate and 5-FU combination was much greater
in asymptomatic patients with advanced CRC than in symptomatic
patients (40 vs 4%, Po0.001), and survival correlated with
performance status, but this was a post hoc analysis in a
nonrandomised trial (Pyrhonen and Kouri, 1992).
Inconclusive results from these two studies and a range of
opinions among medical oncologists who treat CRC led us to
evaluate whether asymptomatic patients should receive chemo-
therapy immediately or could defer therapy without compromising
outcomes. Two almost identical prospective, randomised con-
trolled trials were undertaken by the Australasian Gastrointestinal
Trials Group (AGITG) and the NSW Clinical Oncology Group, and
the National Cancer Institute of Canada (NCIC) Clinical Trials
Group. The primary aim of both studies was to evaluate the effect
of the early use of 5FU–LV on survival of asymptomatic patients
with advanced CRC. Quality of life was a secondary outcome. We
report here a preplanned, prospective meta-analysis of survival
and QoL of the two studies.
PATIENTS AND METHODS
Patient population
Patients were recruited from 17 hospitals in Australasia (Australia
and New Zealand) and 17 hospitals in Canada between May 1994
and October 1999. Patients in both studies were required to have
histologically proven CRC with local recurrence or metastases not
amenable to curative treatment. Patients were required to have
no symptoms related to advanced disease, specified as: no pain
requiring regular narcotic analgesics; no weight loss over 5kg
(unless related to surgery or other illness); no persistent nausea
requiring medication; ECOG performance status of 0 or 1 (Canada:
Karnofsky performance status 490%); no obstructive bowel
symptoms; no persistent fever related to metastatic cancer; and
no other symptom which in the opinion of the clinician was due
to progressive metastatic cancer. Other eligibility criteria included:
no prior chemotherapy for metastatic disease (patients might have
received 5FU-based adjuvant treatment more than 6 months before
the development of metastatic disease); evaluable or measurable
disease according to the criteria of Miller (Miller et al, 1981);
creatinine o150mml
 1 or creatinine clearance 41mls
 1; bili-
rubin o25mml
 1, aspartate aminotransferase (AST) o2 upper
limit of normal (ULN), alanine transferase (ALT) o3 ULN;
granulocytes 41.5 10
9l
 1, platelets 4100 10
9l
 1; no central
nervous system metastases; no history of prior invasive malignant
disease; and no uncontrolled medical condition that would be
aggravated by treatment. Women of childbearing potential had to
be not pregnant and agree to adequate contraception for the
duration of the study. The study was approved by local
institutional ethics committees, and written informed consent
was obtained.
Pretreatment evaluation included patient history, physical
examination, clinical tumour measurement, full blood cell count,
electrolytes, urea, creatinine, liver function tests (bilirubin, AST,
ALT), albumin, calcium and glucose, chest X-ray, electrocardio-
gram and radiological investigations as indicated to document
evaluable or measurable disease. Serum lactate dehydrogenase
measurement was mandated in Australasian patients only.
Randomisation and treatment
Patients were stratified according to treatment centre and prior
adjuvant chemotherapy (yes or no), then randomised to immediate
treatment (to begin within 2 weeks) or treatment delayed until the
development of symptoms.
The treatment schedule differed in the Australasian and
Canadian studies. In Canada, the study allowed only the Mayo
clinic schedule: (5FU 425mgm
 2 intravenous (i.v.) bolus on days
1–5, LV 20mgm
 2 i.v. bolus on days 1–5, repeated every 28 days).
In Australasia, clinicians chose between the Mayo clinic schedule
or weekly 5FU–LV (5FU 500mgm
 2 i.v. bolus and LV 20mgm
 2
i.v. bolus), but nominated the schedule before randomisation
(Buroker et al, 1994; Kerr et al, 2000). Every attempt was made to
treat all patients for at least 2 months.
For patients allocated to delayed treatment, chemotherapy was
started when defined criteria were met. These criteria included
a decline in performance status to ECOG X2 or Karnofsky o90%,
weight loss more than 4.0kg from the time of study entry,
persistent nausea requiring medication, pain requiring regular
narcotic analgesics, elevation of bilirubin to 425mml
 1 due to
metastatic disease, elevation of AST or ALT to 43 ULN, other
symptoms due to progressive cancer, development of clinically
significant third-space fluid collections or if it was felt that further
delays in instituting chemotherapy would be unwise.
Dose modifications were undertaken according to the toxicity in
the previous cycle. Patients with no toxicity at all could have the
5FU dose increased by 50mgm
 2. Grade p2 nonhaematological
toxicity or nadir neutrophil counts X0.5 10
9l
 1 or platelets
X50 10
9l
 1 did not require dose modification. Grade 3
nonhaematological toxicity or nadir neutrophil counts
o0.5 10
9 or platelets o50 10
9l
 1 warranted 5FU dose reduc-
tion by 50mgm
 2. Any grade 4 toxicity warranted reduction by
100mgm
 2. Patients whose measures on laboratory parameters
had not returned to pretreatment levels at the time of the next
cycle or week of therapy had treatment withheld weekly for a
maximum of 2 weeks to allow recovery.
Evaluations of patients
All patients were reviewed monthly throughout the study period
with history and physical examination, performance status, full
blood cell count and serum biochemistry. Assessments of QoL
were completed every 2 months and tumour imaging every 3
months. Patients with responding disease (assessed by standard
criteria; Miller et al, 1981) continued on treatment. Treatment was
discontinued if there was evidence of disease progression,
intolerable toxicity despite dose reductions, completion of six
cycles of chemotherapy with best response being only stable
disease, or at the patient’s request.
In both trials, QoL assessment was undertaken every 2 months
to provide a direct comparison of QoL with and without
chemotherapy. Both studies used the European Organisation for
the Research and Treatment of Cancer (EORTC) QLQ-C30, which
is a well-validated, comprehensive, core questionnaire consisting
of 30 items that assess function, symptoms and overall QoL
(Aaronson et al, 1991). The Canadian questionnaire had three
more questions than QLQ-C30. Identical questions were combined
for the analysis.
Additional instruments used in Australasia included the linear
analogue self-assessment (LASA) scales of Priestman and Baum
(1976), the GLQ-8 scales of Coates et al (1983) and the QL index of
Spitzer et al (1981).
Statistical analysis
Continuous variables were presented as medians with interquartile
ranges. Australasian and Canadian studies were combined in a
prospective meta-analysis for the primary outcome of survival and
also time to ultimate disease progression (time from randomisa-
tion until first evidence of progression after chemotherapy). Risk
factors considered in univariate and multivariate analysis of
predictors of survival and time to ultimate progression included
age, sex, performance status, weight, stage at diagnosis and
disease-free interval. Outcomes were analysed with the Cox
proportional-hazards regression model (with stratification by trial
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sfor combined analysis), with hazard ratio and 95% confidence
intervals (CIs) reported. Relevant variables were adjusted for in a
multivariate model. Survival curves were presented as Kaplan–
Meier plots. All analyses used SPIDA and SAS (versions 7 and 8)
software, classified data by intention to treat, and were two-sided
with a 5% level of significance.
Combined data for baseline-adjusted EORTC QLQ-C30 scores
for overall QoL and individual domains of QoL for treatment
groups were compared. Quality of life scores are rarely normally
distributed, and the data distributions in this study were skewed;
presenting means and standard deviations was not appropriate.
Therefore, the data were dichotomised into ‘good’ and ‘poor’
categories, with proportions and 95% CIs presented graphically for
the ‘good’ QoL scores by treatment group and time. Alternatively,
medians and interquartile ranges could have been presented;
however, the scales were small and presenting medians would not
show subtle differences.
The primary objective of each trial was to detect differences in
overall survival. The intended combined sample size of 400
patients had 83% power to detect a 15% absolute improvement in
1-year survival from 40 to 55% at a 5% significance level. As both
trials collected common QoL data using the QLQ-C30 question-
naire, there was good power (490%) to detect small differences in
QoL from the combined studies. With the final sample size of 168
patients (median follow-up of 57 months), the combined analysis
would have an 80% power to detect a 20% improvement in 1-year
survival (from 45 to 65%).
RESULTS
Patient characteristics and treatment
Owing to slow accrual, recruitment was suspended before the
predetermined sample size for each study was reached. However,
the prospective meta-analysis was still conducted as intended.
A total of 168 patients were recruited (101 Australasians, 67
Canadians) (Figure 1). Patient demographic characteristics and
factors of potential prognostic importance were generally well
168 eligible patients
recruited
(Australasian 101,
Canadian 67)
Randomisation
84 immediate treatment
(Australasian 50,
Canadian 34)
84 immediate treatment
(Australasian 50,
Canadian 33)
83 received protocol therapy
1 refused treatment 
59 received protocol therapy
12 refused treatment 
  2 remained asymptomatic 
  8 died early 
  3 were given radiotherapy 
83 died
1 alive at the time of analysis
80 died
4 alive at the time of analysis
Figure 1 Progress of patients in the Australasian and Canadian
colorectal cancer trials.
Table 1 Characteristics at baseline of patients with asymptomatic colorectal cancer in two trials
Australasia Canada
Immediate Delayed Immediate Delayed
Characteristic n¼50 n¼51 n¼34 n¼33
Median age (years) 66.8 65.3 67.4 63.7
Age range (years) 46–80 36–77 56–80 50–78
Aged 470 years (n, %) 17 (34) 8 (16) 13 (38) 7 (21)
Female (n, %) 12 (24) 14 (27) 8 (24) 9 (27)
ECOG performance status
0( n, %) 42 (84) 38 (75) 34 (100) 33 (100)
1( n, %) 8 (16) 13 (25) 0 0
Karnofsky performance status
100 (n, %) NA NA 14 (41) 21 (64)
90 (n, %) NA NA 20 (59) 12 (36)
Measurable disease 50 (100) 51 (100) 24 (71) 25 (76)
Sites of disease
a
Peritoneal cavity (n, %) NA NA 5 (15) 4 (12)
Liver (n, %) 39 (83) 34 (71) 23 (68) 24 (73)
Lung (n, %) 10 (21) 17 (35) 12 (35) 10 (30)
Lymph nodes (n, %) 7 (15) 9 (19) NA NA
Other (n, %) 9 (19) 11 (23) 21 (62) 12 (36)
Weight loss (n, %) 7 (14) 9 (18) NA NA
Prior adjuvant chemotherapy (n, %) 14 (28) 12 (24) 9 (26) 8 (24)
Stage IV at first presentation (n, %) 19 (38) 12 (24) NA NA
Disease-free interval 412 months (n, %) NA NA 14 (41) 13 (39)
Treatment-free interval (months) NA NA 9–58 13–46
NA¼not available.
aPatients could have more than one site of disease.
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sbalanced between the immediate- and delayed-treatment arms
(Table 1). The median age was similar across immediate and
delayed groups for both studies, although there were more patients
aged over 70 years in the immediate-treatment groups. All
Canadian patients had ECOG performance status 0, whereas 21%
of Australasian patients had ECOG performance status 1 on the
basis of comorbidity. All Australasian patients had measurable
disease, whereas 26% of Canadian patients had only evaluable,
nonmeasurable disease. The most common sites of metastases
were liver and lung.
Only one patient randomised to the immediate-treatment group
did not receive protocol therapy, deciding to defer treatment until
the disease had progressed. In the delayed-treatment group, 59
(70%) ultimately received protocol (5FU–LV) therapy. Of the
remaining 25 patients in the delayed-treatment group, 12 declined
chemotherapy at the decision point and were subsequently
managed by supportive care (seven), radiotherapy (one), immedi-
ate chemotherapy (one), other chemotherapy in a research study
(one), and care unknown (two). Two patients had not developed
symptoms by 55 and 57 months after randomisation, respectively.
Eight patients died before starting therapy 2.2–53 months after
randomisation; of these, seven died of progressive disease and one
died of postoperative complications after presenting with acute
bowel obstruction related to peritoneal metastases. Three patients
were treated with radiation therapy alone.
No patients received second-line systemic treatments, since
neither irinotecan nor oxaliplatin were available during the study
period.
All Canadian patients received the Mayo clinic schedule of four-
weekly 5FU–LV (Table 2). In the Australasian cohort, 22 of 49
patients in the immediate-treatment group and 12 of 33 treated
patients in the delayed-treatment group received weekly 5FU–LV.
In the delayed-treatment group, the median time from randomisa-
tion to treatment initiation was 6 months (range 1–34) in the
Australasian cohort and 4 months (1–28) in the Canadian cohort.
Reasons for starting treatment in the delayed-treatment group
were onset of symptoms (pain (23%), declining performance status
(29%), weight loss (20%), nausea (6%), elevated bilirubin (4%),
elevated transaminases (6%)), and significant disease progression
without protocol-specified increased symptoms (13%).
Time to disease progression
The time to disease progression from randomisation to after
chemotherapy was similar in the immediate- and delayed-
treatment groups for both studies (Table 3). Pooling the results
of the two studies by meta-analysis (test for heterogeneity,
P¼0.047) did not disclose a difference in time to disease
progression between the immediate- and delayed-treatment
groups. Disease progression occurred at a median of 10.2 months
after randomisation in patients receiving immediate treatment,
and 10.8 months in the delayed treatment group (hazard ratio,
1.01; 95% CI 0.72–1.41). After adjustment for age, sex, weight,
ECOG performance status, prior adjuvant chemotherapy, and
baseline QoL, the hazard ratio was similar.
Survival
In September 2004, the median follow-up time was 55 months, and
163 patients had died (83 in the immediate-treatment group and 80
in the delayed-treatment group). In all, 89% of patients died from
Table 2 Treatment received by patients with asymptomatic colorectal cancer in two trials
Australasia Canada
Immediate Delayed Immediate Delayed
Treatment details n¼50 n¼51 n¼34 n¼33
Protocol chemotherapy (n, %) 49 (98) 33 (65) 34 (100) 26 (79)
Regimen
Weekly FU–LV (n, %) 22 (44) 12 (24) NA NA
4-weekly FU–LV (n, %) 27 (54) 21 (41) 34 (100) 26 (79)
Number of treatment cycles (median, interquartile range) 6 (3–8) 4.5 (1.5–7.5) 6 (3–8) 3 (2–6)
Delay to treatment start (median, range, in months)
a 0 (0–1) 6 (1–34) 0 (0) 4 (1–28)
NA¼not available; FU–LV¼5-fluorouracil and leucovorin.
aOnly patients who began treatment are included in this analysis.
Table 3 Median time to event for patients with asymptomatic colorectal cancer in two trials
Immediate treatment Delayed treatment
Outcome n¼84 n¼84 Hazard ratio (95% CI) P-value
Time to disease progression (months)
Australasian trial 13.0 12.0 1.11 (0.72–1.70) 0.65
Canadian trial 7.7 8.4 0.89 (0.52–1.51) 0.65
Total 10.2 10.8 1.01 (0.72–1.41) 0.95
Adjusted
a 1.08 (0.71–1.64) 0.73
Survival (months)
Australasian trial 15.5 11.9 1.08 (0.73–1.62) 0.70
Canadian trial 11.9 10.2 1.07 (0.66–1.76) 0.78
Total 13.0 11.0 1.08 (0.79–1.47) 0.63
Adjusted
a 1.15 (0.77–1.72) 0.49
CI¼confidence interval.
aAdjusted for age, sex, weight, ECOG performance status, prior adjuvant chemotherapy, and baseline quality of life.
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stumour progression, 3% from treatment-related toxicity, and 8%
from other unrelated conditions.
Survival after study entry was similar in the immediate- and
delayed-treatment groups for both the Australasian and Canadian
studies (Table 3). Pooling the results of the two studies by meta-
analysis (test of heterogeneity, P¼0.5) did not show a difference in
survival between the groups. The 1-year survival was 57% for
immediate treatment and 46% for delayed treatment. Median
survival was 13.0 months in patients receiving immediate
treatment and 11.0 months in the delayed-treatment group (hazard
ratio, 1.08; 95% CI 0.79–1.47) (Figure 2). Adjustment for risk
factors did not significantly change the hazard ratio (hazard ratio,
1.15; 95% CI 0.77–1.72).
Multivariate analysis was conducted with the Cox proportional-
hazards model. Age, sex, liver metastases, ECOG performance
status, baseline QoL scores, weight, disease-free interval 412
months, stage at first presentation, and prior adjuvant chemo-
therapy did not statistically significantly influence time to disease
progression or survival for immediate vs delayed treatment.
Quality of life
Patients completed QoL assessments every 2 months from
randomisation until death. The EORTC QLQ-C30 was common
to both the Australasian and Canadian studies. Form completion
rates were high at baseline and at each subsequent time point.
Quality of life was similar for patients in both treatment arms at
baseline. All 168 patients completed questionnaires at baseline,
with over 95% of all questions answered. At 12 months, 85% of
living, immediately treated patients and 74% of living patients
allocated to delayed treatment completed questionnaires. For
global health status, a score higher than 75% was considered to
indicate ‘good’ QoL. Figure 3 shows the proportion of ‘good’ scores
over time by treatment group; a proportion of 0.5 indicates that
half the patients had QoL scores higher than 75%. Global health
status in the immediate treatment group was nonsignificantly
lower at all time points, except at 8 months, when QoL was the
same. There was no statistically significant difference in overall
QoL or any component domain between the two treatment
strategies at baseline or at any subsequent time point.
The use of the LASA scales of Priestman and Baum (1976), the
GLQ-8 scales of Coates et al (1983) and the QL index of Spitzer
et al (1981) showed no differences from the results of the EORTC
scales. Physical well-being (LASA) was rated high at baseline
(median 1cm on a 10cm scale) with nonsignificant deterioration
over time (median 2.2cm at 8 months) with no difference between
immediate- and delayed-treatment groups (data not shown). Scales
for pain, appetite, thought of feeling sick, nausea and vomiting,
and overall QoL showed no differences between treatment groups
or over time. The proportion of patients with a QL index score of 5
(optimal QoL) fell from 60% at baseline to 40% by 14 months, but
with no significant difference between the treatment strategies or
over time (data not shown). The immediate- and delayed-
treatment groups had no significant difference at any time point
in most of the individual domains of QoL in the EORTC and other
instruments (ECOG performance status, dyspnoea, loss of appetite,
constipation, diarrhoea, pain, fatigue, nausea and vomiting, and
physical, role functioning, emotional, and cognitive functioning).
The two exceptions were insomnia and social functioning, in
which those patients in the immediate-treatment group showed a
nonsignificant trend for poorer QoL over time compared with
those in the delayed-treatment group.
Adverse effects
Treatment toxicities were as expected for these regimens of
5FU–LV (Table 4), with no statistically significant differences in
incidence or severity of worst side effects between immediate- and
delayed-treatment groups. Neutropenia occurred in 14% of
patients and infection was uncommon (6% of patients overall),
with no significant difference between patient groups. Grade 3 or 4
stomatitis occurred in 13% of patients, with no difference between
the two arms. Grade 3 or 4 diarrhoea occurred in 20% of patients
overall and was more common in immediately treated patients.
For Australasian patients, a comparison of toxicities for the two
different schedules indicated more grade 3 or 4 diarrhoea with
weekly treatment (24 vs 13%), but less grade 3 or 4 neutropenia (3
vs 9%) and stomatitis (2 vs 8%).
DISCUSSION
In this analysis, no survival benefit could be demonstrated from
the use of immediate 5FU–LV treatment of asymptomatic patients
with metastatic CRC, compared to a policy of watchful waiting
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Figure 2 Survival of patients after randomisation to immediate or
delayed chemotherapy treatment for colorectal cancer (P¼0.6): pooled
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Figure 3 Proportion of patients rating their global health status score
higher than 75% (on EORTC QLQ-C30) at each time point after
randomisation to immediate or delayed chemotherapy treatment for
colorectal cancer. A high score indicates better quality of life. The vertical
lines show 95% CIs. The data points have been offset for clarity. The
number at risk is the number of patients who completed questionnaires.
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sand institution of 5FU–LV when symptoms occurred. This result
occurred even though 25 (30%) patients allocated to delayed
treatment did not receive any chemotherapy. Imbalances in
characteristics between groups were minor and had no significant
effect. Patients on immediate treatment tended to be older, but
adjustment for risk factors including age, performance status,
prior adjuvant chemotherapy, and baseline QoL did not change the
results of the analysis.
Quality of life was not enhanced or adversely affected by
immediate treatment. The data show no significant difference in
overall QoL or any individual domain of QoL between the two
groups, at any time point. Up to the 12-month time-point
completion rates of QoL questionnaires were high and almost
identical between the two treatment arms, indicating reliability
of interpretation. However, beyond 12 months, differences in
completion rates between the two study arms make interpretation
of QoL data difficult, since reasons for noncompletion may vary
between the two treatment strategies.
The patient population studied is typical of the cohort of
patients with metastatic CRC that present without symptoms. All
our patients were of good performance status with 88% of patients
overall having ECOG performance status zero. In the delayed-
treatment group, the median time to the development of symptoms
requiring treatment was 5 months with a very wide range (1–34
months), which was similar to the Nordic trial (179 days, range
5–901 days) (Nordic Gastrointestinal Tumor Adjuvant Therapy
Group, 1992). However, the result of our study is at odds with the
Nordic study, which showed a longer survival for immediate
treatment than for delayed treatment. In that study, patients were
allocated to receive immediate treatment with 12 courses of MFL
(methotrexate, LV, and 5FU), or to ‘primary expectancy’, with
chemotherapy withheld until symptoms occurred. The survival for
immediately treated patients in our study was similar to the Nordic
study, but for delayed-treatment patients, outcome data were
worse in the Nordic study; patients receiving delayed treatment
had shorter symptom-free survival compared to immediate
treatment (2 vs 10 months, Po0.001), poorer survival (median 9
vs 14 months, P¼0.02), and lower 1-year survival (38 vs 55%,
P¼0.03). In our study, delayed treatment patients had a median
time to start of treatment (similar to symptom-free survival) of 5
months and a median survival of 11.0 months, somewhat longer
than the Nordic study. In the Nordic study, two-monthly review
may have compromised the outcome for delayed patients since
significant health deterioration is more likely to have occurred in
the longer review interval compared to our study. Alternatively,
subtle differences in characteristics of patients may account for the
differences in results of the two studies.
At the time our two studies were conceived, we deliberately
intended to perform a meta-analysis to improve sensitivity of
both QoL and survival assessments. Therefore, each study collected
essentially identical data. Unfortunately, it was not considered
feasible to include the Nordic study data into this meta-analysis
for a number of reasons. Firstly, this was a preplanned analysis, free
of any bias as a consequence of knowledge of the individual trial
results. Secondly, the Nordic trial was the study that generated
the questions being asked in these two trials. Thirdly, no formal
comparable QoL assessments were undertaken in the Nordic
trial and the chemotherapy used was not standardised in the
delayed-treatment arm. However, it is possible to undertake a
simplified fixed-effects meta-analysis with the end point of
12-month survival using our two studies as prospective evidence
and the three studies as total evidence, since this end point is
available for all three studies. The results are presented as Table 5,
and show a nonsignificant trend towards improved 12-month
survival for immediate treatment (odds ratio 1.63, 95% CI 0.71–3.7,
P¼0.25).
Slow accrual was a problem in our study, preventing it from
either definitively supporting or refuting the results of the Nordic
study. Many patients and physicians had a preference for either
immediate or delayed treatment and this limited accrual to the
study, even though there was equipoise among oncologists as to
which strategy was appropriate. The small sample size in this study
has resulted in insufficient power to detect modest differences in
survival and QoL between immediate- and delayed-treatment
schedules; by chance, we could have missed a 20% difference in
1-year survival. Nonetheless, the minor trend towards better
survival, lack of trend towards better progression-free survival,
and lack of effect on QoL with immediate treatment suggests that if
real benefits exist for early treatment they are small.
This study demonstrates the problems of compliance with a
management plan involving delayed therapy in patients with
terminal cancers. Only 70% (59 of 84) of patients in the delayed-
Table 5 Comparison of proportion surviving at 12 months
Study Immediate, n/N (%) Delayed, n/N (%) OR 95% CI P-value
Nordic 51/93 (55) 34/90 (38) 2.04 1.13–3.7 0.03
Australasian 31/50 (62) 24/51 (47) 1.84 0.83–4.1 0.13
Canadian 17/34 (50) 15/33 (45) 1.20 0.46–3.1 0.7
All studies
a 1.63 0.71–3.7 0.25
Australia and Canada
b 1.40 0.47–4.1 0.5
OR¼odds ratio; CI¼confidence interval.
aTests for heterogeneity at P¼0.8.
bTests for heterogeneity at P¼0.7.
Table 4 Number of patients with asymptomatic colorectal cancer in two
trials having grade 3 or 4 toxicity
Australasia Canada
Immediate Delayed Immediate Delayed
Type of toxicity (n,% ) n¼49
a n¼31
a n¼34
a n¼26
a
Nausea and vomiting 3 (6) 5 (16) 6 (18) 0 (0)
Stomatitis 1 (2) 4 (13) 9 (26) 4 (15)
Diarrhoea 10 (20) 5 (16) 9 (26) 4 (15)
Dermatitis 0 (0) 0 (0) 0 (0) 1 (4)
Infection 4 (8) 0 (0) 3 (9) 2 (8)
Other 3 (6) 2 (6) 10 (29) 12 (46)
Haemoglobin 0 (0) 1 (3) 0 (0) 2 (8)
White blood cells 0 (0) 0 (0) 3 (9) 5 (19)
Neutrophils 4 (8) 1 (3) 8 (24) 6 (23)
Platelets 0 (0) 1 (3) 0 (0) 0 (0)
Creatinine 0 (0) 0 (0) 1 (3) 0 (0)
Bilirubin 1 (2) 2 (6) 0 (0) 5 (19)
Alkaline phosphatase 1 (2) 7 (23) 0 (0) 1 (4)
Aspartate aminotransferase 0 (0) 0 (0) 0 (0) 0 (0)
Lactate dehydrogenase 7 (14) 7 (23) NA NA
NA¼not applicable.
aNumber receiving protocol therapy.
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streatment group actually received the protocol-defined chemo-
therapy, which was marginally higher than the Nordic study (57%,
51 of 90). One-quarter of our patients not receiving chemotherapy
died early, or were too ill to receive treatment, and one-third chose
alternative treatments. Such compliance issues would tend to bias
this study in favour of immediate treatment. This issue should be
considered in planning any future studies of chemotherapy in this
context.
This study was begun in the early 1990s to address the
fundamental question of timing of chemotherapy in patients with
asymptomatic cancer. At the time the study was conducted, the
thymidylate synthase inhibitors such as 5FU were the only
treatments of demonstrated benefit. The introduction of additional
agents has expanded the range of options for these patients and
debate about the timing of the institution of chemotherapy has
been overtaken by a desire to incorporate these new agents to
achieve the greatest patient benefit (Simmonds, 2000). However,
the newer regimens also bring more toxicity, so the question as to
whether asymptomatic patients with advanced CRC should be
treated remains unanswered (Simmonds, 2000). Certainly the
increased toxicity of irinotecan and oxaliplatin would have greater
adverse effects on QoL in asymptomatic patients, which would
need to be offset by considerable survival gains to make such
treatment worthwhile in this setting. Two recently reported studies
throw some light on this issue. The MRC FOCUS randomised study
accrued 2135 patients and compared a reference treatment of
modified de Gramont schedule 5FU–LV followed by irinotecan
upon primary treatment failure, with four other regimens using
either second-line combination therapy or first-line combination
therapy (Seymour, 2005). None of the combination regimens was
superior to the reference treatment in terms of overall survival
even though a higher response rate was seen. This study suggests
that there is no detriment to use of 5FU–LV as initial treatment
in an asymptomatic patient, reserving more toxic combination
regimens for second-line management. The LIFE study compared
an infusional 5FU–LV regimen alone with the same regimen
plus oxaliplatin in 725 patients (Pluzanska et al, 2005). While the
combination regimen showed better response rate (54 vs 30%,
Po0.0001) and progression-free survival (7.9 vs 5.9 months,
Po0.0001), there was no difference in survival (15.9 vs 15.2
months). Again, these data suggest that 5FU alone is acceptable
as initial management in advanced colorectal cancer, parti-
cularly since QoL is likely to be more greatly affected by a
combination regimen. To date, data on the effect of palliative
chemotherapy on QoL in CRC are insufficient (Conroy et al, 2003).
A large, randomised controlled trial in asymptomatic patients
would be needed to establish the benefit of newer treatments on
patient and cancer outcomes in this subgroup. In the meantime,
the results of the study reported here suggest that immediate
treatment of asymptomatic patients with 5FU–LV is not necessary
to maximise QoL or survival, and that close monitoring and
chemotherapy when symptoms prevail is a reasonable manage-
ment strategy.
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Physician Coordinator; Dr Dongsheng Tu; Ms Ann-Marie Sargeant.
NCIC CTG coordinating centre staff
Dr Lois Shepherd, Physician Coordinator; Ms Ann-Marie Sargeant,
Study Coordinator; Dr Dongsheng Tu, Senior Biostatistician;
Mr Eric Bacon, Biostatistician; Mrs Julia Baran, Clinical Trial
Assistant; Mrs Vicki Classen, Assistant.
NCCTG staff
Ms Jeannine A Hadley, Study Coordinator; Dr Daniel Sargent,
Biostatistician; Dr Heff Sloan, Quality of Life Coordinator.
AGITG trial team
Professor Stephen Ackland (Study Chairman), Newcastle Mater
Hospital; Dr David Bell, Royal North Shore Hospital; Professor
Michael Findlay, Wellington Hospital; Professor John Simes,
NHMRC Clinical Trials Centre, University of Sydney; A/Professor
Michael Solomon, Royal Prince Alfred Hospital; Professor John
Zalcberg, Peter MacCallum Cancer Institute; Mr Mark Jones,
NHMRC Clinical Trials Centre; Ms Jennifer Yuen, NHMRC Clinical
Trials Centre; Ms Haryana Dhillon, NHMRC Clinical Trials Centre.
AGITG coordinating centre, NHMRC Clinical Trials
Centre, staff
Ms Elaine Beller, Biostatistician, Trial Manager; A/Professor Val
Gebski, Senior Biostatistician; Mr Mark Jones, Biostatistician; Ms
Jennifer Yuen, Study Coordinator; Ms Yan Ping Zhang, Study
Coordinator; Ms Haryana Dhillon, Trial Manager; Ms Yeon Suk
Baik, Computer Programmer; Ms Sinden Medley, Assistant; Dr
Martin Stockler, Clinical Epidemiologist; Professor John Simes,
Biostatistician and Clinical Trialist.
Contributing investigators
CO.10 Dr J Skillings, QEII Centre for Clinical Research, Halifax;
Dr B Leyland-Jones, McGill University, Montreal; Dr M Belanger,
CHUQ- Pavillon Dieu de Quebec, Quebec; Dr J Latreille, CHUM –
Hotel Dieu du Montreal, Montreal; Dr B Findlay, Hotel Dieu Health
Sciences Hospital, Niagara, St Catharines; Dr J Giesbrecht, Hotel
Dieu Health Sciences Hospital, Niagara, St Catharines; Dr M
Samosh, Hotel Dieu Health Sciences Hospital, Niagara, St
Catharines; Dr C de Gara, Hamilton Regional Cancer
Centre, Hamilton; Dr A Figueredo, Hamilton Regional Cancer
Centre, Hamilton; Dr LA Zibdawi, Southlake Regional Health
Centre, Newmarket; Dr L Rotstein, University Health Network –
Princess Margaret Hospital, Toronto; Dr L Rudinskas, Humber
River Regional Hospital, Toronto; Dr JJ Wilson, Humber River
Regional Hospital, Toronto; Dr R Feld, University Health Network
– Princess Margaret Hospital, Toronto; Dr Malcolm Moore,
University Health Network – Princess Margaret Hospital, Toronto;
Dr D Walde, Algoma Regional Cancer Program, Sault Area
Hospital, Sault Ste. Marie; Dr S Akhtar, Allan Blair Cancer Centre,
Regina; Dr C Fitzgerald, Allan Blair Cancer Centre, Regina; Dr T
Tirona, Allan Blair Cancer Centre, Regina; Dr CKO Williams, Allan
Blair Cancer Centre, Regina; Dr A Maksymiuk, Saskatoon Cancer
Centre, Saskatoon; Dr A Wong, Tom Baker Cancer Centre, Calgary;
Dr A Fields, Cross Cancer Institute, Edmonton; Dr H Rayner,
BCCA – Vancouver Island Cancer Centre, Victoria; Dr B Weiner-
man, BCCA – Vancouver Island Cancer Centre, Victoria; Dr JE
Krook, SMDC Cancer Centre, Duluth; Dr RM Rowland, NCCTG
Operations Office, Rochester; Dr MM Veeder, NCCTG Operations
Office, Rochester.
AG9401 Professor AS Coates, Royal Prince Alfred Hospital,
Sydney; Professor MPN Findlay, Royal Prince Alfred Hospital,
Sydney; A/Professor DR Bell, Royal North Shore Hospital, Sydney;
Dr H Gurney, Westmead Hospital, Sydney; Dr B Brigham, Prince
of Wales Hospital, Sydney; Dr C Lewis, Prince of Wales Hospital
Sydney; Professor ML Friedlander, Prince of Wales, Sydney;
Dr D Dalley, St Vincent’s Hospital Sydney; A/Professor J Grygiel,
St Vincent’s Hospital, Sydney; Dr S Della-Fiorentina, Liverpool
Hospital, Sydney; Dr E Moylan, Liverpool Hospital, Sydney; Dr A
Bonaventura, Newcastle Mater Misercordiae Hospital, Newcastle;
Professor SP Ackland, Newcastle Mater Misercordiae Hospital,
Newcastle; Dr JF Stewart, Newcastle Mater Misercordiae Hospital,
Newcastle; A/Professor E Abdi, Bendigo Hospital, Bendigo;
Professor JR Zalcberg, Austin-Repatriation Medical Centre; Dr
P Mitchell, Austin-Repatriation Medical Centre; Dr R McIntosh,
Townsville Base Hospital, Townsville; Dr J Norman, Queen
Elizabeth II Hospital, Adelaide; Dr D Kotasek, Queen Elizabeth II
Hospital, Adelaide; Professor R Lowenthal, Royal Hobart Hospital,
Hobart; Dr M Jeffrey Christchurch Hospital, Christchurch; Dr M
Costello, Dunedin Hospital, Dunedin; Dr D Perez, Dunedin
Hospital, Dunedin; Dr S Allan, Palmerston North Hos-
pital, Palmerston North; Dr R Isaacs, Palmerston North Hospital,
Palmerston North; Dr G Forgeson, Palmerston North Hospital,
Palmerston North.
Early 5FU in asymptomatic metastatic CRC
SP Ackland et al
1243
British Journal of Cancer (2005) 93(11), 1236–1243 & 2005 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s